Streamlining Aetna Xarelto Prior Authorization for Rivaroxaban

Successfully navigating Aetna Xarelto prior authorization is critical for ensuring timely patient access to this direct oral anticoagulant. Klivira automates the submission and tracking processes, integrating directly with payer systems.

For revenue cycle directors and prior authorization coordinators, managing pharmacy benefit prior authorizations like those for Xarelto (rivaroxaban) with Aetna presents unique challenges. Understanding the specific submission channels, utilization management criteria, and potential denial patterns is essential for maintaining efficient workflows and reducing administrative burden. Klivira provides the operational clarity and automation needed to optimize these complex interactions.

Understanding Aetna's Requirements for Xarelto (Rivaroxaban)

Xarelto (rivaroxaban) is a direct oral anticoagulant (DOAC) indicated for conditions such as atrial fibrillation and venous thromboembolism (VTE). As a pharmacy-benefit medication, its prior authorization with Aetna is primarily managed through CVS Caremark, Aetna's PBM. Formulary tier placement and step therapy requirements vary by plan and necessitate careful review of Aetna's specific Clinical Policy Bulletins (CPBs).

Aetna's Pharmacy Benefit Prior Authorization Channels

For outpatient retail and mail-order prescriptions like Xarelto, Aetna routes pharmacy-benefit PA requests through established electronic prior authorization (ePA) partners. Submissions for retail pharmacy are typically processed via CoverMyMeds or Surescripts ePA, while mail-order and case-managed scenarios may route through CVS Caremark's direct provider portal. It is crucial to select the correct channel based on the patient's benefit and pharmacy type.

Navigating Aetna's Utilization Management Criteria for Rivaroxaban

Aetna's medical necessity criteria for Xarelto are published within its Clinical Policy Bulletins (CPBs), accessible in the public Aetna CPB library. These CPBs specify clinical indications, step therapy protocols, and any quantity limits that must be met for approval. Klivira's platform is designed to help identify and align documentation with these payer-specific criteria, minimizing the risk of administrative denials.

Common Denial Reasons for Xarelto Prior Authorization with Aetna

Prior authorization denials for rivaroxaban often stem from insufficient documentation of medical necessity, failure to meet step therapy requirements, or off-label use without compendium support. Quantity limits or site-of-service mismatches can also lead to denials. Understanding the X12 CARC and RARC vocabularies used in electronic remittance is key to interpreting these denials and preparing effective appeals.

Aetna Prior Authorization Turnaround Times and Compliance

Aetna's PA turnaround times are influenced by state-mandated minimums for commercial plans and NCQA Utilization Management accreditation standards. For Medicare Advantage plans, Aetna is an impacted payer under CMS-0057-F, which mandates 72-hour decisions for standard PA requests and 24-hour decisions for expedited requests, with phased compliance through 2027. Klivira's proactive tracking helps ensure compliance with these critical timelines.

Leveraging Klivira for Aetna Xarelto PA Automation

Klivira integrates with your EMR system and Aetna's designated ePA partners, including CoverMyMeds and Surescripts, to automate the submission and monitoring of Xarelto prior authorizations. Our platform streamlines the intake of clinical data, ensures adherence to Aetna's CPB requirements, and provides real-time status updates, significantly reducing manual effort and accelerating patient access to critical medications.

Frequently asked questions

Which Aetna entity handles Xarelto prior authorizations?

As Xarelto (rivaroxaban) is a pharmacy-benefit drug, prior authorizations are primarily handled by CVS Caremark, which serves as Aetna's Pharmacy Benefit Manager (PBM) since the CVS Health acquisition.

What are the primary submission channels for Xarelto PA with Aetna?

For retail pharmacy prescriptions, Xarelto PA requests are typically submitted electronically via ePA partners like CoverMyMeds or Surescripts. For mail-order and specific case-managed scenarios, submissions may be routed through CVS Caremark's direct provider portal.

Where can I find Aetna's medical necessity criteria for rivaroxaban?

Aetna publishes its medical necessity criteria, including those for rivaroxaban (Xarelto), within its Clinical Policy Bulletins (CPBs). These are publicly available in the Aetna CPB library and outline specific indications, step therapy, and quantity limit requirements.

Does Aetna require step therapy for Xarelto?

Step therapy requirements for Xarelto (rivaroxaban) vary by Aetna plan and are detailed within the applicable Clinical Policy Bulletins (CPBs). It is essential to consult the specific CPB for the patient's plan to understand any preceding therapy requirements.

How do CMS-0057-F regulations impact Aetna Xarelto prior authorizations?

CMS-0057-F directly impacts Aetna's Medicare Advantage plans, requiring 72-hour decisions for standard PA and 24-hour for expedited requests, with phased compliance deadlines. While not directly applicable to commercial lines, these regulations set a precedent for electronic PA efficiency and transparency.